Patent: 10,030,051
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,030,051
Title: | Antibody targeting through a modular recognition domain |
Abstract: | The present invention provides antibodies containing one or more modular recognition domains (MRDs) for targeting the antibodies to specific sites. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also provided in the invention. |
Inventor(s): | Barbas, III; Carlos F. (La Jolla, CA) |
Assignee: | The Scripps Research Institute (La Jolla, CA) |
Application Number: | 14/963,722 |
Patent Claims: | see list of patent claims |
Details for Patent 10,030,051
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2028-01-03 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2028-01-03 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | See Plans and Pricing | 2028-01-03 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |